New vaccines and antiviral drugs for cytomegalovirus
The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactiv...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Griffiths, Paul [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2019transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
4 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management - Scheen, Marc ELSEVIER, 2022, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:116 ; year:2019 ; pages:58-61 ; extent:4 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.jcv.2019.04.007 |
|---|
| Katalog-ID: |
ELV047045124 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV047045124 | ||
| 003 | DE-627 | ||
| 005 | 20230626014828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191021s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2019.04.007 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000662.pica |
| 035 | |a (DE-627)ELV047045124 | ||
| 035 | |a (ELSEVIER)S1386-6532(19)30095-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.45 |2 bkl | ||
| 100 | 1 | |a Griffiths, Paul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a New vaccines and antiviral drugs for cytomegalovirus |
| 264 | 1 | |c 2019transfer abstract | |
| 300 | |a 4 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. | ||
| 520 | |a The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. | ||
| 650 | 7 | |a Pre-emptive therapy |2 Elsevier | |
| 650 | 7 | |a Cytomegalovirus |2 Elsevier | |
| 650 | 7 | |a Letermovir |2 Elsevier | |
| 650 | 7 | |a Valganciclovir |2 Elsevier | |
| 650 | 7 | |a Maribavir |2 Elsevier | |
| 650 | 7 | |a Brincidofovir |2 Elsevier | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Scheen, Marc ELSEVIER |t Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |d 2022 |g Amsterdam [u.a.] |w (DE-627)ELV007727844 |
| 773 | 1 | 8 | |g volume:116 |g year:2019 |g pages:58-61 |g extent:4 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jcv.2019.04.007 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.45 |j Immunologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 116 |j 2019 |h 58-61 |g 4 | ||
| author_variant |
p g pg |
|---|---|
| matchkey_str |
griffithspaul:2019----:evcieadniiadusoc |
| hierarchy_sort_str |
2019transfer abstract |
| bklnumber |
44.45 |
| publishDate |
2019 |
| allfields |
10.1016/j.jcv.2019.04.007 doi GBV00000000000662.pica (DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Griffiths, Paul verfasserin aut New vaccines and antiviral drugs for cytomegalovirus 2019transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:116 year:2019 pages:58-61 extent:4 https://doi.org/10.1016/j.jcv.2019.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 116 2019 58-61 4 |
| spelling |
10.1016/j.jcv.2019.04.007 doi GBV00000000000662.pica (DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Griffiths, Paul verfasserin aut New vaccines and antiviral drugs for cytomegalovirus 2019transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:116 year:2019 pages:58-61 extent:4 https://doi.org/10.1016/j.jcv.2019.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 116 2019 58-61 4 |
| allfields_unstemmed |
10.1016/j.jcv.2019.04.007 doi GBV00000000000662.pica (DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Griffiths, Paul verfasserin aut New vaccines and antiviral drugs for cytomegalovirus 2019transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:116 year:2019 pages:58-61 extent:4 https://doi.org/10.1016/j.jcv.2019.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 116 2019 58-61 4 |
| allfieldsGer |
10.1016/j.jcv.2019.04.007 doi GBV00000000000662.pica (DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Griffiths, Paul verfasserin aut New vaccines and antiviral drugs for cytomegalovirus 2019transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:116 year:2019 pages:58-61 extent:4 https://doi.org/10.1016/j.jcv.2019.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 116 2019 58-61 4 |
| allfieldsSound |
10.1016/j.jcv.2019.04.007 doi GBV00000000000662.pica (DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 DE-627 ger DE-627 rakwb eng 610 VZ 44.45 bkl Griffiths, Paul verfasserin aut New vaccines and antiviral drugs for cytomegalovirus 2019transfer abstract 4 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier Enthalten in Elsevier Science Scheen, Marc ELSEVIER Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management 2022 Amsterdam [u.a.] (DE-627)ELV007727844 volume:116 year:2019 pages:58-61 extent:4 https://doi.org/10.1016/j.jcv.2019.04.007 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.45 Immunologie VZ AR 116 2019 58-61 4 |
| language |
English |
| source |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:116 year:2019 pages:58-61 extent:4 |
| sourceStr |
Enthalten in Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management Amsterdam [u.a.] volume:116 year:2019 pages:58-61 extent:4 |
| format_phy_str_mv |
Article |
| bklname |
Immunologie |
| institution |
findex.gbv.de |
| topic_facet |
Pre-emptive therapy Cytomegalovirus Letermovir Valganciclovir Maribavir Brincidofovir |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| authorswithroles_txt_mv |
Griffiths, Paul @@aut@@ |
| publishDateDaySort_date |
2019-01-01T00:00:00Z |
| hierarchy_top_id |
ELV007727844 |
| dewey-sort |
3610 |
| id |
ELV047045124 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047045124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626014828.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2019.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000662.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047045124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(19)30095-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Griffiths, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New vaccines and antiviral drugs for cytomegalovirus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pre-emptive therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytomegalovirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Letermovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Valganciclovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Maribavir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brincidofovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:116</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:58-61</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2019.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">116</subfield><subfield code="j">2019</subfield><subfield code="h">58-61</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| author |
Griffiths, Paul |
| spellingShingle |
Griffiths, Paul ddc 610 bkl 44.45 Elsevier Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir New vaccines and antiviral drugs for cytomegalovirus |
| authorStr |
Griffiths, Paul |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV007727844 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.45 bkl New vaccines and antiviral drugs for cytomegalovirus Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir Elsevier |
| topic |
ddc 610 bkl 44.45 Elsevier Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir |
| topic_unstemmed |
ddc 610 bkl 44.45 Elsevier Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir |
| topic_browse |
ddc 610 bkl 44.45 Elsevier Pre-emptive therapy Elsevier Cytomegalovirus Elsevier Letermovir Elsevier Valganciclovir Elsevier Maribavir Elsevier Brincidofovir |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| hierarchy_parent_id |
ELV007727844 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV007727844 |
| title |
New vaccines and antiviral drugs for cytomegalovirus |
| ctrlnum |
(DE-627)ELV047045124 (ELSEVIER)S1386-6532(19)30095-2 |
| title_full |
New vaccines and antiviral drugs for cytomegalovirus |
| author_sort |
Griffiths, Paul |
| journal |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| journalStr |
Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2019 |
| contenttype_str_mv |
zzz |
| container_start_page |
58 |
| author_browse |
Griffiths, Paul |
| container_volume |
116 |
| physical |
4 |
| class |
610 VZ 44.45 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Griffiths, Paul |
| doi_str_mv |
10.1016/j.jcv.2019.04.007 |
| dewey-full |
610 |
| title_sort |
new vaccines and antiviral drugs for cytomegalovirus |
| title_auth |
New vaccines and antiviral drugs for cytomegalovirus |
| abstract |
The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. |
| abstractGer |
The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. |
| abstract_unstemmed |
The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| title_short |
New vaccines and antiviral drugs for cytomegalovirus |
| url |
https://doi.org/10.1016/j.jcv.2019.04.007 |
| remote_bool |
true |
| ppnlink |
ELV007727844 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.jcv.2019.04.007 |
| up_date |
2024-07-06T21:49:25.606Z |
| _version_ |
1803867983033925632 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV047045124</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626014828.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">191021s2019 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2019.04.007</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000662.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV047045124</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(19)30095-2</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.45</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Griffiths, Paul</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">New vaccines and antiviral drugs for cytomegalovirus</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2019transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">4</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The natural history of cytomegalovirus (CMV) infection in transplant patients has been well established. This virus may originate from the recipient, the donor or both. When pre-transplant IgG antibodies in the recipient are taken into account, three types of infection are possible: primary, reactivation or reinfection. The risks of high viral load and end-organ disease are highest after primary infection and lowest after reactivation. Serial monitoring of patients by quantitative polymerase chain reaction for CMV DNA allows antiviral drugs to be deployed for pre-emptive therapy or an antiviral drug may be given prophylactically.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pre-emptive therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Cytomegalovirus</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Letermovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Valganciclovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Maribavir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Brincidofovir</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Scheen, Marc ELSEVIER</subfield><subfield code="t">Kidney disease in antiphospholipid antibody syndrome: Risk factors, pathophysiology and management</subfield><subfield code="d">2022</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV007727844</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:116</subfield><subfield code="g">year:2019</subfield><subfield code="g">pages:58-61</subfield><subfield code="g">extent:4</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.jcv.2019.04.007</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.45</subfield><subfield code="j">Immunologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">116</subfield><subfield code="j">2019</subfield><subfield code="h">58-61</subfield><subfield code="g">4</subfield></datafield></record></collection>
|
| score |
7.4021845 |